SUSAN G. KOMEN® UNVEILS $26 MILLION INVESTMENT IN RESEARCH FOCUSED ON METASTATIC BREAST CANCER AND NEW TREATMENTS

 

 

 

 

 

FOR IMMEDIATE RELEASE

Mackenzie Sadler
Komen Greater Atlanta
(404) 876-2875
msadler@daltonagency.com

SUSAN G. KOMEN® UNVEILS $26 MILLION INVESTMENT IN RESEARCH FOCUSED ON METASTATIC BREAST CANCER AND NEW TREATMENTS  

Georgia Researchers to Receive $446,402 in Research Funding

ATLANTA (SEPTEMBER 16, 2019) – Susan G. Komen®, the world’s leading breast cancer organization, today announced $26 million in funding for new research projects that focus on metastatic breast cancer, developing new, more-effective treatments and addressing disparities in breast cancer outcomes.

“In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer,” said George Sledge, Susan G. Komen’s co-Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.

“We are pleased to be able to support research aimed at preventing breast cancers from metastasizing (spreading) and developing new, more effective treatments for metastatic disease,” added Komen’s co-Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry and Otolaryngology at Vanderbilt University School of Medicine.

More than an estimated 154,000 women in the U.S. are living with metastatic breast cancer – the most advanced stage of breast cancer that has spread outside the breast, often to the brain, bones, liver and lungs. Currently, there is no cure for metastatic breast cancer, and it is responsible for almost all the 42,000 breast cancer deaths in the U.S. each year.

Among the 60 grants Komen awarded, 38 are focused on better understanding and treating metastatic breast cancer. Grants were also given to researchers who are developing new therapies for breast cancer including aggressive subtypes such as triple negative breast cancer, investigating drug resistance, and addressing health disparities in breast cancer outcomes among specific communities.

“Breast cancer does not affect everyone equally and with the grants we’re funding this year, we’re moving closer to new therapies for aggressive forms of cancer, understanding why treatment doesn’t work in some patients and making sure everyone has access to the care they need,” said Paula Schneider, CEO, Susan G. Komen.

Komen’s 2019 portfolio includes*:

  • 60 grants totaling $25,689,384. Of these:
    • Metastatic Breast Cancer (38 grants)
    • Development of New Therapies (39 grants)
    • Treatments for Triple Negative Breast Cancer (16 grants)
    • Drug Resistance (14 grants)
    • Disparities in Breast Cancer Outcomes (9 grants)
    • Big Data Technology for Breast Cancer Research (5 grants)

*Eds Note: Numbers add to more than 60 because individual studies may be classed in more than one category.

These new funds bring Komen’s total research investment in breast cancer to more than $1 billion since opening its doors in 1982, and Komen’s investment in research focused on metastatic breast cancer to $210 million. Since 1991, Komen Greater Atlanta has invested over $39 million in community programs serving local women and men, while contributing $9,666,392 to Komen research.

Komen’s new research in Georgia includes Lauren McCullough, Ph.D., who will receive $446,402 to study the different factors which can lead to racial differences in breast cancer metastasis mortality. From the factors identified in this study, Dr. McCullough hopes to identify innovative solutions to address racial disparities in metastatic breast cancer.

“We are so thankful for the friends, family and neighbors that fight alongside us, helping to reduce the number of breast cancer deaths in metro Atlanta, both on the ground and through research,” said Cati Diamond Stone, CEO of Komen Atlanta. “Dr. McCullough’s work falls beautifully in line with our focus of eliminating African American breast health disparities and our focus on providing support for those living with metastatic breast cancer.”

####

About Susan G. Komen® Greater Atlanta
Metro Atlanta women are dying of breast cancer more often when compared to women in the U.S. as a whole. And that has to change. Komen Atlanta fights breast cancer on two fronts: at home in metro Atlanta by providing breast health and breast cancer services for those who cannot afford them, and globally by funding cutting edge research to find cures. Komen Atlanta has raised $52.5 million since its inception in 1991, with over $39.7 million invested in Metro Atlanta to save lives locally and over $9.6 million invested to fund research to save lives all over the world. Komen Atlanta is part of the national Susan G. Komen organization, the largest private funder in the fight against breast cancer. For more information visit KomenAtlanta.org.

About Susan G. Komen®
Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide.  We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information.  Born out of a promise between two sisters, Susan G. Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures.

Grants are contingent upon signed and executed contracts with Komen.

 ###